CoChat
Sign Up
Cited by 160Thyroid Disorders and TreatmentsIon Transport and Channel RegulationCardiac electrophysiology and arrhythmias

In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.

Open access
Chan, A, Shinde, R, Chow, C C, Cockram, C S, Swaminathan, R·1991·BMJ
DOI 10.1136/bmj.303.6810.1096
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To examine whether sodium pump activity plays a part in the pathogenesis of thyrotoxic periodic paralysis. DESIGN: Measurement of platelet sodium-potassium ATPase and in vivo sodium pump activities in healthy subjects and thyrotoxic subjects with and without paralysis. SETTING: University hospital in Hong Kong. SUBJECTS: 21 healthy subjects, 23 untreated thyrotoxic subjects, 13 untreated men with periodic paralysis, seven treated thyrotoxic subjects, and six treated men with periodic paralysis. MAIN OUTCOME MEASURES: Platelet Na+, K(+)-ATPase activity and plasma rubidium concentration after oral loading. RESULTS: Median (range) platelet Na+, K(+)-ATPase activity in thyrotoxic subjects was 253 (169-821) mumol inorganic phosphate/h/g protein--significantly higher than that in healthy subjects (134 (81-180) mumol/h/g protein; p less than 0.001). Na+, K(+)-ATPase activity in those with periodic paralysis was 374 (195-1196) mumol/h/g protein, again significantly higher than that in healthy subjects (p less than 0.001) and that in other thyrotoxic subjects (p less than 0.01) despite similar degrees of hyperthyroidism. Activities in treated thyrotoxic subjects with and without periodic paralysis were 148 (110-234) and 131 (86-173) mumol/h/g protein respectively. Mean (95% confidence interval) plasma rubidium concentration five hours after oral administration in thyrotoxic subjects (7.0 (6.6 to 7.5) mumol/l) was significantly lower than in healthy subjects (10.2 (9.5 to 10.9) mumol/l; p less than 0.001) and higher than in those with periodic paralysis (6.0 (5.7 to 6.3) mumol/l; p less than 0.01). CONCLUSIONS: Sodium pump activity in untreated subjects with periodic paralysis is higher than in other thyrotoxic subjects, and this may be responsible for the hypokalaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.303.6810.1096

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The activity of Na+-K+ ATPase pumps in skeletal muscle is significantly increased in TPP.

    “The important role of Na+-K+ ATPase pumps in the pathogenesis of TPP is supported by the finding that their activity in the skeletal muscle is significantly increased.”

    From Thyrotoxic Periodic Paralysis: Clinical Challenges (2014) · cites this paper as [7]

  • Thyrotoxic patients with periodic paralysis have higher sodium pump activity than those without paralytic episodes.

    “Thyrotoxic patients with PP have been found to have higher sodium pump activity than those without paralytic episodes [7].”

    From Thyrotoxic Periodic Paralysis: Clinical Challenges (2014) · cites this paper as [7]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 11

  1. de Wolf F, Goudsmit J, Paul DA, Lange JM, Hooi'jkaas C, Schellekens P, et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. BMJ 1987;295:569-7 1.
  2. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J. Relation between humoral responses in HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ 1991;302: 23-6.
  3. HIV prevalence estimates and AIDS case projections for the United States. MMfIfWYR 1990;39:1-31.
  4. Lini SG, Lee CA, Kernoff PBA. Zidovudine treatment for anti-HIV positive haemophiliacs. Clin Lab Haemtatol 1990;12:367-78.
  5. Swart AM. Weller I, Darbyshire JH. Early HIV infection: to treat or not to treat? B,MJ 1990;301:825-6.
  6. Friedland GH. Early treatmenit for HIV. N EnglJ Med 1990;322:1000-2.
  7. Medina I, Mills J, Leoung G, Hopewell DC, Lee B, Modin G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immuno- deficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N EnglJ Med 1990;323:776-82.
  8. Beard J, Savidge GF. High-dose intravenous immunoglobulin and splenectomy for the treatment of HIV-related immune thrombocytopenia in patients with severe haemophilia. BrJ Haematol 1988;68:303-6.
  9. Lim SG, Lee CA, Kernoff PBA. The treatment of HIV-associated thrombo- cytopenia in haemophiliacs. Clin Lab Haematol 1990;12:237-45.
  10. Pottage JC, Benson CA, Spear JB, Landay AL, Kessler HA. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine. _AAMA 1988;260:3045-8.
  11. Lee CA, Kernoff PBA, Karayiannis P, Thomas HC. Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia. Brj Haematol 1989;72:235-8.

Cited by

Sorted by citations

Related

Authors
Chan, A., Shinde, R., Chow, C. C., Cockram, C. S., & Swaminathan, R.
Affiliations
Chinese University of Hong Kong (HK)
Venue
BMJ
Publisher
BMJ
Published
1991-11-02
Volume
303
Issue
6810
Pages
1096-1099
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
DOI
10.1136/bmj.303.6810.1096
OpenAlex
W2036976592
Cited by
160
References
30
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 5 · 2018: 6 · 2017: 4 · 2016: 3 · 2015: 8 · 2014: 12 · 2013: 9 · 2012: 9
FWCI
1.50
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
Funders
Chinese University of Hong Kong
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
thyrotoxic periodic paralysis, sodium pump activity, Na+/K+-ATPase, platelets, hyperthyroidism, hypokalemia, pathogenesis
MeSH terms
Sodium-Potassium-Exchanging ATPase, Adult, Blood Platelets, Humans, Male, Paralysis, Periodicity, Rubidium, Thyrotoxicosis, Thyrotropin, Thyroxine, Triiodothyronine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review